Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

ClinicalTrials.gov ID: NCT02513160

Public ClinicalTrials.gov record NCT02513160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) forced expiratory volume in 1 second (FEV1) area under the effect curve from time 0 to 6 weeks (AUEC\[0-6wk\]).

Study identification

NCT ID
NCT02513160
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
713 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2015
Primary completion
Mar 30, 2016
Completion
Mar 30, 2016
Last update posted
Nov 8, 2021

2015 – 2016

United States locations

U.S. sites
75
U.S. states
25
U.S. cities
62
Facility City State ZIP Site status
Teva Investigational Site 13415 Peoria Arizona
Teva Investigational Site 13389 Downey California
Teva Investigational Site 13421 Huntington Beach California
Teva Investigational Site 13434 Huntington Beach California
Teva Investigational Site 13427 Los Angeles California
Teva Investigational Site 13386 Mission Viejo California
Teva Investigational Site 13394 Orange California
Teva Investigational Site 13417 Riverside California
Teva Investigational Site 13445 Rolling Hills Estates California
Teva Investigational Site 13420 San Diego California
Teva Investigational Site 13443 San Diego California
Teva Investigational Site 13438 San Jose California
Teva Investigational Site 13397 Centennial Colorado
Teva Investigational Site 13454 Denver Colorado
Teva Investigational Site 13404 Aventura Florida
Teva Investigational Site 13458 Hialeah Florida
Teva Investigational Site 13416 Miami Florida
Teva Investigational Site 13440 Miami Florida
Teva Investigational Site 13455 Miami Florida
Teva Investigational Site 13431 Ormond Beach Florida
Teva Investigational Site 13437 Sarasota Florida
Teva Investigational Site 13425 Tallahassee Florida
Teva Investigational Site 13450 Normal Illinois
Teva Investigational Site 13448 River Forest Illinois
Teva Investigational Site 13408 Lenexa Kansas
Teva Investigational Site 13410 Baltimore Maryland
Teva Investigational Site 13422 Bethesda Maryland
Teva Investigational Site 13435 Wheaton Maryland
Teva Investigational Site 13411 North Dartmouth Massachusetts
Teva Investigational Site 13398 Plymouth Minnesota
Teva Investigational Site 13429 Plymouth Minnesota
Teva Investigational Site 13433 Columbia Missouri
Teva Investigational Site 13432 Rolla Missouri
Teva Investigational Site 13414 St Louis Missouri
Teva Investigational Site 13430 St Louis Missouri
Teva Investigational Site 13384 Bellevue Nebraska
Teva Investigational Site 13392 Brick New Jersey
Teva Investigational Site 13426 Ocean City New Jersey
Teva Investigational Site 13419 Skillman New Jersey
Teva Investigational Site 13388 Rochester New York
Teva Investigational Site 13441 Hickory North Carolina
Teva Investigational Site 13403 Raleigh North Carolina
Teva Investigational Site 13405 Wilmington North Carolina
Teva Investigational Site 13395 Canton Ohio
Teva Investigational Site 13396 Cincinnati Ohio
Teva Investigational Site 13436 Sylvania Ohio
Teva Investigational Site 13423 Toledo Ohio
Teva Investigational Site 13387 Oklahoma City Oklahoma
Teva Investigational Site 13453 Eugene Oregon
Teva Investigational Site 13439 Lake Oswego Oregon
Teva Investigational Site 13402 Medford Oregon
Teva Investigational Site 13412 Portland Oregon
Teva Investigational Site 13391 Pittsburgh Pennsylvania
Teva Investigational Site 13449 East Providence Rhode Island
Teva Investigational Site 13456 Warwick Rhode Island
Teva Investigational Site 13413 North Charleston South Carolina
Teva Investigational Site 13390 Knoxville Tennessee
Teva Investigational Site 13442 Knoxville Tennessee
Teva Investigational Site 13400 Austin Texas
Teva Investigational Site 13452 Boerne Texas
Teva Investigational Site 13407 Dallas Texas
Teva Investigational Site 13424 Dallas Texas
Teva Investigational Site 13409 El Paso Texas
Teva Investigational Site 13451 Houston Texas
Teva Investigational Site 13399 New Braunfels Texas
Teva Investigational Site 13393 San Antonio Texas
Teva Investigational Site 13444 San Antonio Texas
Teva Investigational Site 13446 San Antonio Texas
Teva Investigational Site 13457 San Antonio Texas
Teva Investigational Site 13459 San Antonio Texas
Teva Investigational Site 13383 Waco Texas
Teva Investigational Site 13401 South Burlington Vermont
Teva Investigational Site 13385 Richmond Virginia
Teva Investigational Site 13447 Richmond Virginia
Teva Investigational Site 13428 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02513160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02513160 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →